This is more specific than they said in the June 7th release:"In...

This is more specific than they said in the June 7th release:

"In June 2022, the company announced that a multi-drug, genomically-guided study in brain
metastases run by the Alliance for Clinical Trials in Oncology had seen the paxalisib arm
graduate to an expansion cohort in patients with breast cancer brain metastases, having
seen positive efficacy signals in the initial exploratory cohort. Paxalisib continues to recruit
to the exploratory cohort in two other patient subgroups." (my bold)